<DOC>
	<DOCNO>NCT02461407</DOCNO>
	<brief_summary>The purpose study compare effect safety Anlotinib placebo patient Gastric Cancer .</brief_summary>
	<brief_title>Study Anlotinib Patients With Gastric Cancer ( ALTER0503 )</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>1 . Signed date informed consent ; 2 . Pathologically confirm advanced gastric adenocarcinoma ( include Gastroesophageal junction adenocarcinoma ) measurable lesion outside stomach ( RECIST 1.1 ) 3 . Advanced stomach cancer patient fail second line high line chemotherapy treatment 4 . &gt; =18 year old；ECOG PS：0~1；Estimated life expectancy &gt; 3 month 5 . Main organ function normal ; 1 . Patients treat anlotinib previously ; 2 . Patients treat VEGFRTKI smallmolecule drug previously , sunitinib , Sorafenib , famitinib , Apatinib , Regorafenib , ect 3 . Patients suffer malignancy currently within 5 year , except cured cervical carcinoma situ , nonmelanoma skin cancer superficial bladder cancer [ Ta ( noninvasive carcinoma ) , Tis ( carcinoma situ ) T1 ( carcinoma invasion lamina propria ) ] 4 . Systemic anticancer therapy schedule 4 week prior assignment study，including cytotoxic therapy，signal transduction inhibitors，immunotherapy ( receive mitomycin C within 6 week study ) . Extended field radiotherapy ( EFRT ) use within 4 week prior assignment limited field radiotherapy use assess tumor lesion within 2 week prior assignment ; 5 . CTCAE ( 4.0 ) Grade 1 high nonremission toxicity induce previous treatments，excluding alopecia Grade 2 low neurotoxicity induce oxaliplatin ; 6 . Patients clear tendency gastrointestinal bleeding ; 7 . Patients factor could affect oral medication ( dysphagia，chronic diarrhea etc . ) 8 . Patients pleural effusion ascites , cause respiratory syndrome ( CTCAE Grade 2 high dyspnea [ Grade 2 dyspnea refers Shortness breath small amount activity , affect Instrumental activity daily life ] ) 9 . Patients severe and/or unable control diseases ; 10 . Patients underwent major surgical treatment，open biopsy significant traumatic injury within 28 day prior assignment ; 11 . Patients physical sign bleed diathesis medical history , matter serious degree ; Patients CTCAE Grade 3 high bleeding event occur within 4 week prior assignment ; Patients nonhealing wounds，ulcers fracture ; 12 . Patients arterial venous thromboembolic event occur within 6 month , cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism ; 13 . Patients drug abuse history unable get rid Patients mental disorder 14 . Brain metastasis patient symptom symptom control &lt; 2 month ; 15 . Patients participate anticancer drug clinical trial within 4 week Patients participate clinical trial ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>